High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients - Abstract

Institute of Pathology, University of Bern, CH-3010 Bern, Switzerland.


CD10 predicts survival in different cancers. The prognostic significance in bladder cancer still has to be documented. One hundred fifty lymph node-positive bladder cancer patients were treated by cystectomy and standardized pelvic lymphadenectomy in curative intent. CD10 expression was evaluated in tissue microarrays (TMAs) constructed from histopathological normal urothelium, primary tumor (tumor center and invasion front), and corresponding lymph node metastases and correlated with tumor characteristics (stage, extracapsular extension, number, and total diameter of metastases) and survival. CD10 expression was successively lost from normal urothelium to primary tumor to metastases (P < .05) and decreased from the tumor center to the invasion front (P < .002). High CD10 expression in tumor center or invasion front (P < .05) but not in the metastases predicted favorable outcome; the prognostic information in the tumor center was independent from tumor stage and lymph node parameters. High CD10 expression level was not associated with specific tumor characteristics. A well-defined sampling strategy for TMAs allows detection of specific biomarker expression patterns and may generate prognostic information inherent in particular tumor areas. The favorable outcome in bladder cancer patients with high CD10 expression might suggest a tumor suppressive function of CD10.

Written by:
Seiler R, von Gunten M, Thalmann GN, Fleischmann A.   Are you the author?

Reference: Hum Pathol. 2011 Aug 9. Epub ahead of print.
doi: 10.1016/j.humpath.2011.04.030

PubMed Abstract
PMID: 21835428

UroToday.com Bladder Cancer Section